Gastrointestinal Cancer

>

Latest News

Phase 3 EMERALD-1 trial results reveal that no new adverse events were identified with durvalumab plus bevacizumab in patients with unresectable HCC.
Durvalumab Plus Bevacizumab Improves PFS Outcomes in Unresectable HCC

January 17th 2025

Phase 3 EMERALD-1 trial results reveal that no new adverse events were identified with durvalumab plus bevacizumab in patients with unresectable HCC.

Results from the CodeBreaK 300 trial helped lead to the approval of sotorasib/panitumumab in KRAS G12C-mutated CRC.
FDA Approves Sotorasib/Panitumumab in KRAS G12C-Mutated CRC

January 16th 2025

Adding lenvatinib/pembrolizumab to TACE elicits a numerical overall survival improvement in the LEAP-012 trial, although additional follow-up is necessary.
TACE Plus Lenvatinib/Pembrolizumab Boosts PFS in Unresectable Liver Cancer

January 16th 2025

Phase 1 data support the fast track designation for invikafusp alfa in advanced colorectal cancer with high tumor mutational burden.
Invikafusp Alfa Earns FDA Fast Track Designation in Locally Advanced CRC

January 10th 2025

Data suggest a need for international preventive strategies and educational efforts regarding the increasing incidence of early-onset colorectal cancer.
Early-Onset Colorectal Cancer Incidence Has Risen on Global Scale

January 8th 2025

Latest CME Events & Activities

2025 GI Satellite Symposia in San Francisco

January 23-24, 2025

Register Now!

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

View More

Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

View More

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

View More

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

View More

<1
...
4849505152